Covid-19 Rates by Time since Vaccination during Delta Variant Predominance
Gabriela Paz‐Bailey, Maya Sternberg, Kiersten J. Kugeler, Brooke Hoots, Avnika B. Amin, Amelia G. Johnson, Bree Barbeau, Nagla S. Bayoumi, Daniel Bertolino, Rachelle Boulton, Catherine Brown, Katherine Busen, Maaike Cima, Cherie Drenzek, Ashley Gent, Gillian Haney, Liam Hicks, Sarah Hook, Amanda Jara, Amanda Jones, Ishrat Kamal-Ahmed, Sarah Kangas, FNU Kanishka, Saadiah I. Khan, Samantha Kirkendall, Anna Kocharian, B. Casey Lyons, Priscilla Lauro, Donald B. McCormick, Chelsea McMullen, Lauren Milroy, Heather E. Reese, Jessica Sell, Allison Sierocki, Elizabeth Smith, Daniel M. Sosin, Emma Stanislawski, Kyle Strand, Thomas Troelstrup, Kathryn Turner, Hailey Vest, Sydni Warner, Caleb Wiedeman, Benjamin J. Silk, Heather M. Scobie
Abstract
BACKGROUND: With the emergence of the delta variant, the United States experienced a rapid increase in Covid-19 cases in 2021. We estimated the risk of breakthrough infection and death by month of vaccination as a proxy for waning immunity during a period of delta variant predominance. METHODS: Covid-19 case and death data from 15 U.S. jurisdictions during January 3 to September 4, 2021 were used to estimate weekly hazard rates among fully vaccinated persons, stratified by age group and vaccine product. Case and death rates during August 1 to September 4, 2021 were presented across four cohorts defined by month of vaccination. Poisson models were used to estimate adjusted rate ratios comparing the earlier cohorts to July rates. RESULTS: During August 1 to September 4, 2021, case rates per 100,000 person-weeks among all vaccine recipients for the January to February, March to April, May to June, and July cohorts were 168.8 (95% confidence interval [CI], 167.5 to 170.1), 123.5 (95% CI, 122.8 to 124.1), 83.6 (95% CI, 82.9 to 84.3), and 63.1 (95% CI, 61.6 to 64.6), respectively. Similar trends were observed by age group for BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccine recipients. Rates for the Ad26.COV2.S (Janssen-Johnson & Johnson) vaccine were higher; however, trends were inconsistent. BNT162b2 vaccine recipients 65 years of age or older had higher death rates among those vaccinated earlier in the year. Protection against death was sustained for the mRNA-1273 vaccine recipients. Across age groups and vaccine types, people who were vaccinated 6 months ago or longer (January-February) were 3.44 (3.36 to 3.53) times more likely to be infected and 1.70 (1.29 to 2.23) times more likely to die from COVID-19 than people vaccinated recently in July 2021. CONCLUSIONS: Our study suggests that protection from SARS-CoV-2 infection among all ages or death among older adults waned with increasing time since vaccination during a period of delta predominance. These results add to the evidence base that supports U.S. booster recommendations, especially for older adults vaccinated with BNT162b2 and recipients of the Ad26.COV2.S vaccine. (Funded by the Centers for Disease Control and Prevention.).